<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">
Log In

SmartTRAK Life Sciences News and Analysis Blog

David Shepard

Lead Analyst, Orthobio & Regen

Recent Posts

3 min read

Medical Care for NFL Teams: Standards and Initiatives from AOSSM 2025

By David Shepard on 8/5/25 9:30 AM

James Voos, MD, chair of the Department of Orthopedics and Sports Medicine at University Hospitals Cleveland Medical Center, Cleveland Browns team physician, and president of the NFL Physicians Society (NFLPS), shares his goals for the society and offers insight into how he is using biotechnology to monitor recovery, prevent further injuries, and safely return athletes to competition.

James Voos, MD, president of the NFL Physicians Society (NFLPS), discusses the society's efforts to standardize care for NFL players across the league in an interview with SmartTRAK at the American Orthopaedic Society for Sports Medicine (AOSSM) 2025 Annual Meeting recently held in Nashville, TN.

Dr. Voos also shares an update on ongoing clinical research for osteoarthritis treatment with stem cells. To listen to the interview, please click on the following video (4:18 minutes). A link to download a complete transcript of the interview is alsoprovided below. 

 

SmartTRAK: Hi, this is Dave Shepard. I'm here at the AOSSM 2025. Keep watching for my interview with Dr. James Voos, who is the team physician for the Cleveland Browns, and also the president of the NFL Physicians’ Society. Dr. Voos, thanks for joining us.

James Voos, MD:
 Thank you very much for the invitation. I appreciate it.

Excellent. Tell me a little bit about the NFL PS and a little bit about what you're doing, what your initiatives are, what your goals are.

JV: 
As president of the NFL Physician Society, we represent all of the physicians that provide care for our professional athletes in football. That's not only our orthopedic surgeons, but our medical physicians and all of our associated consultants. So we help to provide standards for how to practice across the league, and that way we assure that every athlete and every team has ...

Interested in how biotechnology can be used to monitor recovery, prevent further injuries and safely return athletes to competition? Click
the button below to download the full transcript of SmartTRAK GM/Sr Analyst David Shepard's interview of James Voos, MD, president of the NFL Physicians Society (NFLPS) from AOSSM 2025. Get the Transcript

Continue Reading
2 min read

BA Summit and AANA Join Forces to Share Orthobiologic Insights

By David Shepard on 7/8/25 9:30 AM

SmartTRAK provides insights into the latest trends, research and consensus opinions in surgical Orthobiologic treatments and non-operative regenerative medicine from this year’s BA Summit and AANA meetings.

Continue Reading
2 min read

FDA Guidance Documents Could Seriously Impact Access to Allograft Tissue

By David Shepard on 6/17/25 9:44 AM

Companies breathe a temporary sigh of relief as the FDA reissues its guidance documents that could reduce allograft availability.

Manufacturers of allograft tissue and the medical device companies that market these products felt more at ease as the FDA reissued guidance set to take effect on May 4, with a new deadline for public comment on July 7. According to the American Association of Tissue Banks (AATB), the recommendations in their current form could reduce the availability of allograft tissues by 40%. The FDA’s recommendations aim to mitigate the risk of sepsis and Mycobacterium tuberculosis (Mtb) transmission when screening potential donors.

The tissue and blood banking industries have urged the agency to withdraw its current guidance and engage in a dialogue to review the actions already taken to mitigate the risk of disease transmission related to sepsis and Mtb. In this article, SmartTRAK examines new FDA recommendations, the concerns raised by these associations and their potential impact on the more than 2.5MM tissue transplants and over 15MM blood transfusions performed annually.

The topics covered in this downloadable SmartTRAK Perspective article are:

  • Background to the Release of the Guidance Document 
  • Origin of the Issue
  • Guidelines Published by the FDA 
  • Coordinated Response and Concerns from Trade Organizations
  • Companies and Products Potentially Impacted
  • Next Steps 

Click the button below to download and read the complete "FDA Guidance Documents Could Seriously Impact Access to Allograft Tissue" article by  David Shepard, SmartTRAK Lead Analyst, Orthobio & Regen.Get the Article

Continue Reading
3 min read

Aatru Medical: Next-Gen NPWT for Surgical Incisions

By David Shepard on 6/3/25 9:30 AM

Thomas Lash, COO and co-founder of Aatru Medical, talks about the company’s innovative single-use negative pressure device, NP-Sims, a Negative Pressure Surgical Incision Management System.

Thomas Lash, chief operating officer and co-founder of Aatru Medical elaborates on the company’s strategy to mitigate the risk of surgical site infections through NP-SIMS, their single-use negative pressure surgical incision management system. To listen to the interview, please click on the following video (21:21 minutes). A link to download a complete transcript of the interview is provided below. 

 

SmartTRAK: Hi, this is David Shepard, senior analyst with SmartTRAK. Today it's my pleasure to be joined by Tom Lash, COO and co-founder of Aatru. He's going to talk to us today about a product that he co-invented, called NPSims. Tom, tell us a little about your company and about the product.

Tom Lash: We started the business about eight years ago, a small research and commercialization team with the goal of developing an alternative solution for the single-use, disposable negative pressure wound therapy market.  Kind of a mouthful to say that, but in essence, what we were trying to do is looking at the predicate devices that are on the market, we knew that if we were going to try and have a product that could make an impact on that market segment, it would be necessary for us to find an innovative mode of action to create the negative pressure without the current use of electromechanical pump which powers the leading products that are in use today. They have an electromechanical pump. They're battery-operated. They have software. Those products were primarily devised for the open or chronic wound market, and because of our focus on the surgical incision market, we were able to design something that was different. We believe the current products are probably over-engineered for the surgical incision market. So, our approach was to devise ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with  Aatru Medical's Co-Founder and COO Thomas Lash, conducted by  David Shepard, SmartTRAK Lead Analyst, Orthobio & Regen.Get the Transcript

Continue Reading
  • There are no suggestions because the search field is empty.

Recent Articles